Press Releases Year None2024202320222021202020192018201720162015201420132012 November 21, 2024 Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering November 20, 2024 Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering November 14, 2024 Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update November 7, 2024 Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024 October 14, 2024 Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit September 25, 2024 OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium September 18, 2024 Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop August 13, 2024 Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference August 8, 2024 Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update August 1, 2024 Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 July 2, 2024 Lineage Cell Therapeutics Added to Membership of 2024 Russell 3000® Index May 30, 2024 Lineage to Present at 2024 BIO International Convention May 21, 2024 Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium May 9, 2024 Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update May 6, 2024 OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit May 2, 2024 Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 April 30, 2024 Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM) April 29, 2024 Lineage Announces Changes to Board of Directors April 1, 2024 Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development March 18, 2024 Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium March 13, 2024 RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit March 11, 2024 RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting March 7, 2024 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update February 29, 2024 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024 February 13, 2024 Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury February 9, 2024 Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering February 6, 2024 Lineage Cell Therapeutics Announces $14.0 Million Registered Direct Offering January 16, 2024 RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS
November 21, 2024 Lineage Cell Therapeutics Announces First Closing of up to $66 Million Registered Direct Offering
November 20, 2024 Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
November 14, 2024 Lineage Cell Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
November 7, 2024 Lineage Cell Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
October 14, 2024 Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare Summit
September 25, 2024 OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium
September 18, 2024 Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology Workshop
August 13, 2024 Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 8, 2024 Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 1, 2024 Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
May 9, 2024 Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 6, 2024 OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
May 2, 2024 Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
April 1, 2024 Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
March 18, 2024 Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
March 13, 2024 RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
March 11, 2024 RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
March 7, 2024 Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024 Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
February 13, 2024 Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
February 9, 2024 Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
January 16, 2024 RG6501 (OpRegen®) Phase 1/2a Results Will Be Featured at 2024 Angiogenesis Exudation and Degeneration Meeting in Presentation by Allen Ho, MD, FACS, FASRS